Oct 1, 2024 · Cobenfy is also being developed as an adjunctive therapy in patients who have an inadequate response to atypical antipsychotic monotherapy. The ongoing Phase III ARISE trial is a six-week, randomised, double-blind, placebo-controlled, multicentre, outpatient study in patients with schizophrenia with an inadequate response to their current atypical antipsychotic treatment.

Jul 2, 2024 · Insurers and government programmes may be reluctant to cover costly treatments. In August 2017, Kymriah broke ground by becoming the first CAR T-cell therapy in the world to gain approval to treat acute lymphoblastic leukaemia in the US, followed closely by Yescarta.

The AI advantage in discovering new medicines With continued investment and growing buzz from the industry, the AI hype is expected to extend through 2025 and beyond.

Dec 2, 2024 · The popularity of GLP-1 receptor (GLP-1R) subcutaneous treatments for obesity has proved the demand for the drugs, but the lack of oral alternatives represents a significant (and profitable) gap, according to an analyst at GlobalData.. Pharmaceuticals analyst Jasper Morley said that the race to be first to market is already on, commenting: “With expected drug sales …

Dec 23, 2024 · Most significant clinical trials of 2024. From GLP-1RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read outs of 2024.

Clinical Trials Arena Excellence Awards 2024 – Winners Announced! The Clinical Trials Arena Excellence Awards Winners have been announced! To see the full list you can download the full…

Oct 27, 2021 · The analytics dashboard of the new platform provides patient recruitment transparency and foster communication, as well as engagement. It also allows study teams to consolidate the recruited patients from different sources.

Nov 19, 2024 · Dr. Steven Nissen, MD chairman and chief academic officer of the Heart and Vascular Institute at the Cleveland Clinic and professor of medicine at the Lerner College of Medicine, reported that subcutaneous injections of 300mg or 450mg of zerlasiran, administered every 16 or 24 weeks, reduced time-averaged Lp(a) levels by 80% to 85% over a follow-up …

Sep 13, 2024 · The vaccine was safe and well tolerated in the first cohort, with adverse events (AEs) including fatigue, injection site pain and fever. Researchers are asking for the interim data to be treated with caution at this early stage due to the small sample size and primary endpoint being safety and dose-determining.

Feb 2, 2023 · Although most early clinical research into mRNA vaccines was dominated by institutions and government agencies, the tables have quickly turned. “mRNA technology is new and successful, and it looks like it’s going to be the next big breakthrough,” says Dr. Harvey Friedman, University of Pennsylvania, who is researching mRNA vaccines for herpes.